Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma

Cited by (494)

Items 301–400 of 494

1. A novel pyroptosis-regulated gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma
   Baozhu Zhang, Zhan Wang · 2022 · Frontiers in Molecular Biosciences
2. neoepiscope improves neoepitope prediction with multi-variant phasing
   Mary Ann Wood, Austin Nguyen, Adam J. Struck, Kyle Ellrott, Abhinav Nellore, Reid F. Thompson · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
3. Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy
   Sultana Mehbuba Hossain, Grégory Gimenez, Peter A. Stockwell, Robert J. Weeks, Suzan N. Almomani, Gregory T. Jones, Magdalena Ratajska, Mathew Shuen, Basharat Ahmad Bhat, Janusz Ryś et al. · 2025 · Cancer Letters
4. Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
   Ka‐Won Noh, Yuri Tolkach, Doris Helbig, Vincenzo Mitchell Barroso, Yannick Foerster, Max S. Schlaak, Tilo Biedermann, Reinhard Büttner, Oana‐Diana Persa · 2025 · Clinical Cancer Research
5. The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer
   Erica V. Carballo, Paula I. González Ericsson, Brian David Lehmann et al. · 2025 · Clinical Cancer Research
6. Small-cell lung cancer: anatomy of an immune-cold tumor
   David Millrine, Kathryn Simpson, Fiona Helen Blackhall, Caroline Dive · 2025 · Trends in cancer
7. PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy
   Sijin Liu, Zhaoting Yang, Biao Wang, Shuyu Huan, Zixi Li, Xunbin Wei, Guoquan Liu · 2026 · Redox Biology
8. Somatic structural variants drive distinct modes of oncogenesis in melanoma
   Jake R. Conway, Riaz Gillani, Jett P. Crowdis, Brendan Michael Reardon, Jihye Park, Seunghun Han, Breanna M. Titchen, Mouadh Benamar, Rizwan Haq, Eliezer M. Van Allen · 2024 · Journal of Clinical Investigation
9. Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: What is the Evidence?
   Nora Chok, Samer Chokr · 2018 · Journal of Neoplasm
10. Biomarkers of response to immune checkpoint inhibitors for metastatic castration resistant prostate cancer: looking for the needle in the haystack
    Husam A. Alqaisi, Esmail Mutahar Al-Ezzi, Aaron Richard Hansen · 2020 · Annals of Translational Medicine
11. Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma
    Jun Wei Zhu, Tenghui Han, Shoujie Zhao, Yejing Zhu, Shouzheng Ma, Fenghua Xu, Tingting Bai, Yuxin Tang, Yungang Xu, Lei Liu · 2022 · Frontiers in Oncology
12. Modification of m5C regulators in sarcoma can guide different immune infiltrations as well as immunotherapy
    Shusheng Wu, Mengge Li, Rixin Su, Hao Shen, Yifu He, Yangfan Zhou · 2023 · Frontiers in Surgery
13. Development a m6A regulators characterized by the immune cell infiltration in stomach adenocarcinoma for predicting the prognosis and immunotherapy response
    Guodong Shi, Yang Li, H.-J. Gao, Yucheng Wei, Yuanyong Wang · 2023 · Aging
14. Integrated analysis identities Rho GTPases related molecular map in patients with gastric carcinoma
    Shaowei Ma, Ying Wang, Weibo Li, Shaofan Qiu, Xiangyu Zhang, Ren Niu, Fangchao Zhao, Yu Zheng · 2023 · Scientific Reports
15. Circadian rhythm related genes identified through tumorigenesis and immune infiltration-guided strategies as predictors of prognosis, immunotherapy response, and candidate drugs in skin cutaneous malignant melanoma
    Chengling Liu, Xingchen Liu, Pengjuan Cao, Haiming Xin, Xin Li, Sailing Zhu · 2025 · Frontiers in Immunology
16. Crosstalk of angiogenesis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in colorectal adenocarcinoma
    Guoliang Cui, Jinhui Liu, Manli Wang · 2022 · Frontiers in Immunology
17. Assessment of genetic diversity in Narbon vetch (Vicia narbonensis L.) germplasm using morphological and molecular markers
    Siwar Bouabid, Houda Chennaoui Kourda, A. Boussaha · 2018 · Australian Journal of Agricultural Research
18. Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas
    Zewei Tu, Qiankun Ji, Qing Han, Xiaoyan Long, Jingying Li, Lei Wu, Kai Huang, Xingen Zhu · 2022 · BMC Cancer
19. Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient
    Sandro Anchisi, Anita Wolfer, Bettina Bisig · 2023 · Cancer Biology & Therapy
20. Combined MEK and STAT3 inhibition reprograms stromal inflammation to overcome immunotherapy resistance in pancreatic cancer
    Jashodeep Datta, Xizi Dai, Anna Bianchi, Iago De Castro Silva, Siddharth Mehra, Vanessa T. Garrido, Purushottam Lamichhane, Samara P. Singh, Zhiqun Zhou, Austin R. Dosch et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
21. Targeting ZNF638 activates antiviral immune responses and potentiates immune checkpoint inhibition in glioblastoma
    Deepa Seetharam, Jay S. Chandar, Christian Kieran Ramsoomair, Jelisah Desgraves, Alexandra Alvarado Medina, Anna Jane Hudson, Ava Amidei, Jesús Castro, Vaidya Govindarajan, Sarah Wang et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
22. m6A modification patterns are associated with copy number burden and tumor immune landscape in thyroid cancer
    Liangliang Cai, Tingting Liu, Hujia Hua, Xingyu Jiang, Qian Li · 2023 · BMC Endocrine Disorders
23. Enhanced Prediction of Immune Checkpoint Blockade Response in Melanoma Using Ensemble Learning and a Hybrid Feature Selection Technique
    Basant Badwy, Nagia M. Ghanem, Karim Banawan, Nour Eldin Ismail · 2024 · IEEE Access
24. Identification of SURF4 and RALGAPA1 as promising therapeutic targets in glioblastoma and pan-cancer through integrative multi-omics, CRISPR-Cas9 screening and prognostic meta-analysis
    Fei Wang, Yuxuan Chen, Run Huang, Dengfeng Lu, Juyi Zhang, Yanbo Yang, Hanhan Dang, Meirong Liu, Zhouqing Chen, Xiaoou Sun et al. · 2025 · Cancer Immunology Immunotherapy
25. Integrated Single-Cell and Bulk RNA Sequencing Analysis Identifies a Regulated Cell Death-Related Gene Signature for Predicting Prognosis and Therapeutic Responses in Cutaneous Melanoma
    Jie Tang, Shixing Zhu, Linyu Zhu · 2025 · Journal of Immunotherapy
26. Harnessing Anoikis-Related Gene Signatures for Immunotherapy Precision: A Machine Learning-Driven Predictive and Prognostic Model
    Xuxiang Chen, Kaile Wang, Shuang Zhou, Jin Huang, Haihang Zhang, Chenmou Huang, Changcheng Yang, Jiangzheng Zeng · 2026 · ACS Omega
27. Integrating Machine Learning and Mendelian Randomization Determined a Functional Neurotrophin-Related Gene Signature in Patients with Lower-Grade Glioma
    Cong Zhang, Guichuan Lai, Jielian Deng, Kangjie Li, Liuyi Chen, Xiaoni Zhong, Biao Xie · 2024 · Molecular Biotechnology
28. Grainyhead-like-2, an epithelial master programmer, promotes interferon induction and suppresses breast cancer recurrence
    Ian MacFawn, Joshua C. Farris, Phillip M. Pifer, Naira V. Margaryan, Halima Akhter, Lei Wang, Sebastian A. Dziadowicz, James Denvir, Gangqing Hu, Steven M. Frisch · 2024 · Molecular Immunology
29. Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma
    Huancheng Zeng, Qiongzhi Jiang, Rendong Zhang · 2024 · Scientific Reports
30. A regularized Cox hierarchical model for incorporating annotation information in predictive omic studies
    Dixin Shen, Juan Pablo Lewinger, Eric S. Kawaguchi · 2024 · BioData Mining
31. A comprehensive investigation of associations between cell death pathways and molecular and clinical features in pan-cancer
    Yin He, Xiaosheng Wang · 2024 · Clinical & Translational Oncology
32. Machine learning derived development and validation of extracellular matrix related signature for predicting prognosis in adolescents and young adults glioma
    Pancheng Wu, Yi Zheng, Wei Wu, Beichen Zhang, Yichang Wang, Min Zhou, Ziyi Liu, Zhao Wang, Maode Wang, Jia Wang · 2025 · Scientific Reports
33. Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma
    Xiangqi Chen, Mingjian Piao, Zixiang Zhou, Shanshan Wang, Shuofeng Li, Nan Zhang, Boyu Sun, Kai Liu, Xu Yang, Xiaobo Yang et al. · 2025 · Cancer Immunology Immunotherapy
34. Functional Genome Profiling to Understand Cancer Immune Responsiveness
    Ena Wang, Davide Bedognetti, Francesco Maria Marincola · 2019 · Methods in molecular biology
35. A novel fatty-acid metabolism-based classification for triple negative breast cancer
    Xia Yang, Wen Tang, Yongtao He, Huimin An, Jin Wang · 2023 · Aging
36. Innovative molecular subtypes of multiple signaling pathways in colon cancer and validation of FMOD as a prognostic-related marker
    Zhujiang Dai, Xiang Peng, Xuewei Cui, Yuegui Guo, Jie Zhang, Xia Shen, Chen‐Ying Liu, Yun Liu · 2023 · Journal of Cancer Research and Clinical Oncology
37. Pyroptosis‐related gene signatures are associated with prognosis and tumor microenvironment infiltration in head and neck cancer
    Yan Long, Yadong Wu, Juxiang Peng, Jukun Song, Na Li · 2023 · Health Science Reports
38. ECT2 promotes the occurrence and is a prognostic biomarker of head and neck squamous cell carcinoma
    Shixiong Peng, Jinhang Wang, Naiheng Hei · 2024 · Journal of Cancer
39. Long‑term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD‑L1 expression
    Hitomi Sakai, Masayuki Takeda, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa · 2020 · Molecular and Clinical Oncology
40. Pathogenesis of Zika Virus Infection via Rectal Route
    Laura E. Martínez, Gustavo Garcia, Deisy A. Contreras, Danyang Gong, Ren Sun, Vaithilingaraja Arumugaswami · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
41. Persistent cell proliferation signals correlates with increased glycolysis in tumor hypoxia microenvironment across cancer types
    Jinfen Wei, Kaitang Huang, Meiling Hu, Zixi Chen, Yunmeng Bai, Shudai Lin, Hongli Du · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
42. Genomic analysis of response to neoadjuvant chemotherapy in esophageal adenocarcinoma
    Fereshteh Izadi, Benjamin P. Sharpe, Stella Panagio Breininger et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
43. Faculty Opinions recommendation of Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
    Jordan Berlin · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
44. Is tumor mutational burden predictive of response to immunotherapy?
    Carino Gurjao, Dina I. Tsukrov, Maxim Imakaev, Lovelace J. Luquette, Leonid A. Mirny · 2024 · eLife
45. Unraveling the Single-Cell Spatial Landscapes of Melanoma Brain Metastases
    Artuer Manukyan, Kristin Peters, Helena Radbruch, Florian Roßner, Felicitas Geserick, Florian Roßner, Annika Lehmann, Janine Altmüller, Thomas Conrad, Janine Altmüller et al. · 2025 · medRxiv
46. A Framework to Predict the Molecular Classification and Prognosis of Breast Cancer Patients and Characterize the Landscape of Immune Cell Infiltration
    Kun Zheng, Zhiyong Luo, Yilu Zhou, Lili Zhang, Yali Wang, Xiuqiong Chen, Shuo Yao, Huihua Xiong, Xianglin Yuan, Yanmei Zou et al. · 2022 · Computational and Mathematical Methods in Medicine
47. Integrative bioinformatics and in vitro exploration of EVI2A expression: unraveling its immunological and prognostic implications in kidney renal clear cell carcinoma
    RONG LIU, Sheng Li, Situ Xiong, Fucun Zheng, Xiangpeng Zhan, JIN ZENG, Bin Fu, Songhui Xu, SHAOXING ZHU, Ru Chen · 2024 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
48. Transcriptomic signatures in peripheral CD4+T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation
    Eleni Palli, Matthieu D. Lavigne, Panagiotis Verginis, Themis Alissafi, Amalia N. Anastasopoulou, Georgios Lyrarakis, John M. Kirkwood, Helen J Gogas, Dimitrios C. Ziogas · 2025 · Frontiers in Immunology
49. Interpretable Differential Abundance Signature (iDAS)
    Lijia Yu, Yingxin Lin, Xiangnan Xu, Pengyi Yang, Jean Yee Hwa Yang · 2025 · Small Methods
50. UBE2N as a novel prognostic and therapeutic biomarker of lung adenocarcinoma
    Haofeng Yin, Yibo Xue, Chen Wang, Yanqin Wu, Yuchen Guo, Chunzhen Li, Yunyan Zhang, Shulei Yin, Tiejun Zhao · 2025 · Frontiers in Immunology
51. Targeting Tumor‐Immune Microenvironment with Organoid and Organ‐on‐a‐Chip: An Updated Review
    Sahar Madani, Joseph Benjamin Holman, Muhammad Umer Rajput, Syed Wajahat Ali, Zhengdi Shi, Bensheng Qiu, Anqing Zhang, Chengpan Li, Weiping Ding · 2025 · Advanced Materials Technologies
52. Integrating single-cell and bulk transcriptomes with machine learning reveals a CAF signature for immunotherapy response in dMMR endometrial cancer
    Lu Zhang, Quan Zhang, Mengjie Yang, Mengyao Xu, Qiyuan Li, Qionghua Chen · 2026 · Discover Oncology
53. Inferring Phenotypes of Single Cells Based on the Expression Profiles of Phenotype-Associated Marker Genes in Bulks and Single Cells
    Yin He, Rongzhuo Long, Li Zhao, Xiaosheng Wang · 2026 · Interdisciplinary Sciences Computational Life Sciences
54. CDCSI: a machine learning-based interpretable cell death and cellular senescence index for prognosis improvement, immune landscape characterization, and therapeutic response prediction in head and neck squamous cell carcinoma
    Xiaoqin Luo, Xian He · 2026 · Frontiers in Immunology
55. Single-cell profiling of gastric cancer ascites reveals an epithelial-immune dual phenotype signature predictive for anti-PD-1 immunotherapy responses
    Tianbing Xu, Muyang Yang, Jing Huang, Lisen Lu, Deqiang Deng, Xiujuan Shi, Yao Sun, Jonathan F. Lovell, Z.B Lin, Y B Zheng et al. · 2026 · BMC Medicine
56. Résistance primaire et résistance acquise aux inhibiteurs PD-1
    Daniele Grazziotin Soares, Jean‐Pierre Lotz · 2017 · ONCOLOGIE
57. Clinical Significance and Immune Landscape of Recurrence-Associated Ferroptosis Signature in Early-Stage Lung Adenocarcinoma
    Lilan Yi, Ping Cheong Huang, Yinfang Gu, Guowu Wu, Xiaofang Zou, Longhua Guo, Chunling Wen, Junlin Zhu, Dongdong Zhao · 2022 · Frontiers in Oncology
58. Biomarkers for Melanoma
    Dirk Schadendorf, Keith T. Flaherty, Lyn M. Duncan, Mohammed Kashani–Sabet, Selma Ugurel · 2020 · Springer eBooks
59. Identification of N7-methylguanosine-related miRNAs as potential biomarkers for prognosis and drug response in breast cancer
    D. Dai, Hongkai Zhuang, Mao Shu, Lezi Chen, Long Chen, Hongmei Wu, Bo Chen · 2024 · Heliyon
60. Molecular Landscape and Prognostic Value in the Post-Translational Ubiquitination, SUMOylation and Neddylation in Osteosarcoma: A Transcriptome Study
    Chenguang Jia, Xiaowei Yao, Zhaoliang Dong · 2024 · Journal of Inflammation Research
61. Novel Methods to Overcome Acquired Resistance to Immunotherapy
    Xianda Zhao, Ce Yuan, John Markus Rieth, Dechen Wangmo, Subbaya Subramanian · 2019 · Resistance to targeted anti-cancer therapeutics
62. Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response
    Meghana S. Pagadala, Victoria H. Wu, Eva Pérez‐Guijarro et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
63. Decoding molecular programs in melanoma brain metastases
    Josefine Radke, Elisa Schumann, Julia Onken, Randi Koll, Güliz Acker, Bohdan Bodnar, Carolin Senger, Sascha Tierling, Markus Möbs, Peter Vajkoczy et al. · 2022 · medRxiv
64. Neural Induction: the General Principle for Embryogenesis and Tumorigenesis
    Ying Cao · 2022 · Preprints.org
65. 513 Overcoming hedgehog mediated anti-PD-1 resistance in melanoma through prostaglandin inhibition
    Nicholas C. DeVito, Y‐Van Nguyen, Nagendra Sastry Yarla, Michael P. Plebanek, Balamayooran Theivanthiran, Michael Aksu, Vaibhav Jain, Brent Allen Hanks · 2022 · Regular and Young Investigator Award Abstracts
66. TREM1 + regulatory myeloid cells expand in steatohepatitis-HCC and associate with poor prognosis and therapeutic resistance to immune checkpoint blockade
    Julie Giraud, Domitille Chalopin, Eloïse Ramel, Thomas Boyer, Atika Zouine, Marie‐Alix Derieppe, Nicolas Larmonier, Olivier Adotévi, Brigitte Le Bail, Jean‐Frédéric Blanc et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
67. Overcoming tumor hypoxia
    Alexander Marie-Madeleine Adrianus van der Wiel · 2023
68. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trial
    Teresa Noviello, Anna Maria Di Giacomo, Francesca Pia Caruso et al. · 2023 · medRxiv
69. Construction of a mitochondria genes-based model for prognosis prediction, drug guidance and immune feature analysis in ovarian serous cystadenocarcinoma
    Dongsheng Shen, Chenghao Wu, Zhongyue Ding · 2023 · Research Square
70. Is tumor mutational burden predictive of response to immunotherapy?
    Carino Gurjao, Dina I. Tsukrov, Maxim Imakaev, Lovelace J. Luquette, Leonid A. Mirny · 2023 · eLife
71. 726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study
    Susan Henry, Stephen L. DeWall, Ulka N. Vaishampayan et al. · 2023 · Regular and Young Investigator Award Abstracts
72. 1348 Development of enLIGHTEN™ Alpha-201 herpes simplex viral vectors encoding payloads targeting the tumor microenvironment
    Anne R. Diers, Qiuchen Guo, John D Christie, David M. Krisky, Karen Bouch, Paul Peter Tak, Francesca Barone · 2023 · Journal for ImmunoTherapy of Cancer
73. INHBA/Activin A promotes tumor growth and induces resistance to anti-PD-L1 therapy by suppressing IFN-γ signaling
    Fanglin Li, Longhua Gu, Yongliang Tong et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
74. Integrated germline and somatic features reveal divergent immune pathways driving ICB response
    Timothy J. Sears, Meghana S. Pagadala, Andrea Castro, Ko-Han Lee, JungHo Kong, Kairi Tanaka, Scott Michael Lippman, Maurizio Zanetti, Hannah K. Carter · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
75. WITHDRAWN: Exploring the Interplay of m6A regulators in renal cell carcinoma: Molecular insights and clinical implications
    Muhammad Sarfaraz Iqbal, Kaoqing Peng, Habib Ali · 2024 · Journal of Taibah University Medical Sciences · Retracted
76. Single-Cell RNA Sequencing Reveals Melanoma Cell State-Dependent Heterogeneity of Response to MAPK Inhibitors
    Su Yin Lim, Yingxin Lin, Jenny Lee · 2024 · SSRN Electronic Journal
77. Pre-Treatment DNA Methylome and Transcriptome Profiles Correlate with Melanoma Response to Anti-Pd1 Immunotherapy
    Michael Roger Eccles, Sultana Mehbuba Hossain, Grégory Gimenez, Peter A. Stockwell, Robert J. Weeks, Suzan N. Almomani, Gregory T. Jones, Magdalena Ratajska, Mathew Shuen, Basharat Ahmad Bhat et al. · 2024 · SSRN Electronic Journal
78. Combination oral immunotherapy with IL-10 and IL-12 effectively treats colon tumors via synergistic effects on IL-17 producing T cells and colon epithelial barrier integrity.
    Neal Bhutiani · 2018
79. Comparative analysis of sfRNA in the genome of pre-epidemic and epidemic Zika viruses for host interacting proteins potentially related to the recent epidemic
    Perumal Arumugam Desingu · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
80. Sex-based mutational landscape confers sensitivity to checkpoint blockade immunotherapy in cutaneous melanoma
    Mingming Jia, Tian H. Chi · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
81. A quest through diagnostics and predictive tools and the exploration of new treatment strategies in clinical trials to improve cancer therapy
    Kimberley M. Heinhuis · 2020
82. Immunological Features of Melanoma: Clinical Implications in the Era of New Therapies
    Licia Rivoltini, Agata Cova, Paola Squarcina · 2021 · Springer eBooks
83. TMB detection from primary and metastatic lesions should be considered separately: a pan-cancer study.
    Xiaoling Shang, Chenglong Zhao, Haining Yu · 2020
84. Molecular Signature of Subtypes of Renal cell carcinomas and Immunotherapy strategy
    Jianing Guo, XiaoFei Lv, Bin He · 2021 · Research Square
85. Identification of the Relationships between Tumor Mutation Burden with Immune Infiltrates in Liver Hepatocellular Carcinoma
    家麟 曲 · 2021 · Advances in Clinical Medicine
86. Biomarkers for Melanoma
    Dirk Schadendorf, Keith T. Flaherty, Lyn M. Duncan, Mohammed Kashani–Sabet, Selma Ugurel · 2019 · Springer eBooks
87. A scoring screening system based on machine learning for immunotherapy beneficiaries in triple-negative breast cancer
    Qiheng Gou, Zijian Liu, Yuxin Xie, Yulan Deng, Ji Ma, Jiangping Li, Hong Zheng · 2022 · Research Square
88. Faculty Opinions recommendation of RAC1P29S induces a mesenchymal phenotypic switch via serum response factor to promote melanoma development and therapy resistance.
    Jonathan Chernoff · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
89. Faculty Opinions recommendation of Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells.
    Laurence Crane Eisenlohr, Gabriela L. Cosma · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
90. Faculty Opinions recommendation of Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
    George C. Tsokos · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
91. Constructing Immune Related Prognosis Score Based on Signatures to Predict the Benefit of Immunotherapy in Colorectal Cancer
    Jun Yong Xiang, JunHu Li, YunXiao Liu et al. · 2022 · Research Square
92. Molecular intrinsic subtypes, genomic and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
    Elise Ballot, Loïck Galland, Hugo Mananet, Romain Boidot, Laurent Arnould, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhaï, Silvia Mihaela Ilie, Audrey Hennequin et al. · 2022 · Research Square
93. Development of a novel lipid metabolism-based signature to predict survival and immune response in triple negative breast cancer
    Xia Yang, Wen Tang, Yongtao He, Huimin An, Jin Wang · 2022 · Research Square
94. Malignant Melanoma
    Michael J. Carr, Justin Ko, Susan M. Swetter, Scott Eric Woodman, Vernon K. Sondak, Kim Allyson Margolin, Jonathan S. Zager · 2022 · Wiley eBooks
95. O papel do receptor NLRP1 na resposta imune e progressão do melanoma: uma abordagem in vivo e in sílico
    Vitor Pedro Targhetta · 2022
96. An N6-methyladenosine-Related Classification Predicts Prognosis and Response to Immunotherapy in Prostate cancer
    Yaru Zhu, Zhen Ren, Jianliang Shen et al. · 2023 · Research Square
97. Data from MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors
    Bin Yang, Xi Li, Yu Fu, Ensong Guo, Youqiong Ye, Fuxia Li, Si Liu, Rourou Xiao, Chen Liu, Funian Lu et al. · 2023
98. Data from Protein Signatures of NK Cell–Mediated Melanoma Killing Predict Response to Immunotherapies
    Sabrina Cappello, Hsu‐Min Sung, Christian Ickes et al. · 2023
99. Data from Integrated Genomic Characterization of the Human Immunome in Cancer
    Yongsheng Li, Brandon Burgman, Daniel James McGrail, Ming Hua Sun, Dan Qi, Sachet Ashok Shukla, Erxi Wu, Anna Capasso, Shiaw‐Yih Lin, Catherine J. Wu et al. · 2023
100. Data from FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors
     Viviana Cremasco, Jillian L. Astarita, Angelo L. Grauel, Shilpa Keerthivasan, Kenzie D. MacIsaac, Matthew Charles Woodruff, Michael C. Wu, Lotte Spel, Stephen Santoro, Zohreh Amoozgar et al. · 2023